Tribenoside

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Tribenoside
Accession Number
DB13227
Type
Small Molecule
Groups
Experimental
Description

Anti-inflammatory agent used in edema of extremities, varicose veins & phlebitis.

Structure
Thumb
Synonyms
  • TBGF
  • Tribenosido
  • Tribenosidum
External IDs
21401-BA / Ba 21401 / BG-356
Categories
UNII
Z7N0Y673NU
CAS number
10310-32-4
Weight
Average: 478.585
Monoisotopic: 478.235538815
Chemical Formula
C29H34O6
InChI Key
ULLNJSBQMBKOJH-VIVFLBMVSA-N
InChI
InChI=1S/C29H34O6/c1-2-32-29-26(30)28(34-20-24-16-10-5-11-17-24)27(35-29)25(33-19-23-14-8-4-9-15-23)21-31-18-22-12-6-3-7-13-22/h3-17,25-30H,2,18-21H2,1H3/t25-,26-,27-,28-,29?/m1/s1
IUPAC Name
(3R,4R,5R)-4-(benzyloxy)-5-[(1R)-1,2-bis(benzyloxy)ethyl]-2-ethoxyoxolan-3-ol
SMILES
CCOC1O[C@H]([C@@H](COCC2=CC=CC=C2)OCC2=CC=CC=C2)[C@H](OCC2=CC=CC=C2)[C@H]1O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(4R)-limoneneThe risk or severity of adverse effects can be increased when (4R)-limonene is combined with Tribenoside.
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with 16-Bromoepiandrosterone.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Tribenoside is combined with 19-norandrostenedione.
5-androstenedioneThe risk or severity of adverse effects can be increased when Tribenoside is combined with 5-androstenedione.
AceclofenacThe risk or severity of adverse effects can be increased when Tribenoside is combined with Aceclofenac.
AcemetacinThe risk or severity of adverse effects can be increased when Tribenoside is combined with Acemetacin.
AlclofenacThe risk or severity of adverse effects can be increased when Alclofenac is combined with Tribenoside.
AldosteroneThe risk or severity of adverse effects can be increased when Tribenoside is combined with Aldosterone.
Alendronic acidThe risk or severity of adverse effects can be increased when Tribenoside is combined with Alendronic acid.
AliskirenTribenoside may decrease the antihypertensive activities of Aliskiren.
Food Interactions
Not Available

References

General References
Not Available
External Links
ChemSpider
169970
ChEBI
91780
ChEMBL
CHEMBL3301681
Wikipedia
Tribenoside
ATC Codes
C05CX01 — TribenosideC05AX05 — Tribenoside

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00325 mg/mLALOGPS
logP4.13ALOGPS
logP5.17ChemAxon
logS-5.2ALOGPS
pKa (Strongest Acidic)12.36ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area66.38 Å2ChemAxon
Rotatable Bond Count13ChemAxon
Refractivity133.51 m3·mol-1ChemAxon
Polarizability52.51 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
O-glycosyl compounds
Alternative Parents
Benzylethers / Monosaccharides / Tetrahydrofurans / Secondary alcohols / Oxacyclic compounds / Dialkyl ethers / Acetals / Hydrocarbon derivatives
Substituents
O-glycosyl compound / Benzylether / Benzenoid / Monosaccharide / Monocyclic benzene moiety / Tetrahydrofuran / Secondary alcohol / Oxacycle / Organoheterocyclic compound / Ether
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Drug created on June 23, 2017 14:38 / Updated on August 02, 2018 06:49